| Placebo | Riociguat 2.5 mg–maximum | Riociguat 1.5 mg–maximum | ||||||
---|---|---|---|---|---|---|---|---|---|
 | n | Baseline | Change from baseline | n | Baseline | Change from baseline | n | Baseline | Change from baseline |
PVR (dyn·s·cm–5) | 11 | 1312±763 | -66±632 | 13 | 1130±664 | -250±410 | 7 | 1047±564 | -126±368 |
NT-proBNP (pg/mL) | 12 | 1573±1775 | -46±697 | 13 | 761±1172 | -164±317a | 7 | 1352±1350 | -872±1147a |
WHO FC (%) | 12 | II – 58% | Improved 8% | 15 | II – 67% | Improved 21% | 8 | II – 50% | Improved 29% |
 |  | III – 42% | Stabilized 83% |  | III – 33% | Stabilized 79% |  | III – 50% | Stabilized 71% |
 |  |  | Worsened 8% |  |  | Worsened 0%a |  |  | Worsened 0%a |
Borg dyspnea score | 12 | 4.3±2.7 | -0.1±2.4 | 15 | 2.5±1.4 | -0.3±1.3b | 8 | 3.2±1.6 | -0.8±0.8a |
EQ-5D score | 12 | 0.74±0.16 | -0.05±0.22 | 15 | 0.78±0.15 | 0.03±0.18a | 8 | 0.74±0.08 | +0.09±0.14a |
LPH score | 12 | 40.4±20.0 | -0.1±15.8 | 15 | 34.9±26.0 | -8.0±15.9a | 8 | 40.0±15.3 | -13.7±13.2a |